Wantstats
Company ProfilePremium

Osiris Therapeutics, Inc

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Osiris Therapeutics, Inc - Healthcare showcase

Year Founded & Workforce

1992

500 Employees

Industry

Healthcare

Services

Amniotic Membrane
O

Osiris Therapeutics, Inc Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Osiris Therapeutics, Inc Overview

Company Headquarter: Maryland, US

Founded: 1992

Workforce: 500+

Company Working: Osiris Therapeutics, Inc. (Osiris) researches, develops, manufactures, and commercializes regenerative medicines intended to improve the health and lives of patients and lower the overall healthcare costs. Osiris has achieved commercial success with products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix, BIO4 and Cartiform. The company has demonstrated more than 25 years of leadership in the field of regenerative medicine and currently markets regenerative medicines in wound care, orthopedics, and sports medicine in the form of skin substitutes, bone grafts, and articular cartilage grafts, respectively.

Strategy

Osiris focuses on strategic partnerships with many companies to expand its product portfolio and enter into different markets to become a market leader.

Company Snapshot

$79.7M

Revenue

500

Employees

1992

Founded

SWOT Analysis

Strengths

  • Broad product portfolio Wide geographical presence

Weaknesses

  • No stability in product launches

Opportunities

  • Expansion in untapped regions

Threats

  • Growing competition

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
March 2019AnnouncementOsiris announced the acquisition by Smith and Nephew which is likely to be completed by 2020.
October 2018Product LaunchOsiris launched GrafixPL PRIME, a human placental membrane
November 2015Product LaunchOsiris launched Stravix, a cryopreserved human placental tissue.

Product Offering

  • Osiris Therapeutics, Inc
    • Amniotic Membrane

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: SBU breakup-0 rose from USD 79.7 Mn in 2015 to USD 118.5 Mn in 2017.
Osiris Therapeutics, Inc — By Business Segment
Series (USD Mn)201520162017
SBU breakup-079.7109.4118.5
SBU breakup-14.96.34.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →